9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
The DOI matches its Crossref record; 90 of the 94 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc21-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc21-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the latest American Diabetes Association (ADA) [62], Italian Society of Diabetology (SID) [63] and KDIGO guidelines [64] differentiate the pharmacological approach to T2DM not just based on the target glycaemic values but also taking into account the indicators of high-risk or established atherosclerotic cardiovascular disease, CKD and heart failure.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [62]
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016) · Annals of Internal Medicine · doi:10.7326/m15-2650 · Cited by 682
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652
Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“temshasbeensupported in the literature in adolescents and adults with type 1 diabetes (16,17), and recent evidence suggests that a closed-loop system is superior to sensor-augmented pump therapy for glycemic control and reduction of hypoglycemia over 3 months of comparison in children and adults with type 1 diabetes (…”
BackgroundHermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., Home, P., & on behalf of the Levemir Treat-to-Target Study Group (2006) · Diabetes Care · doi:10.2337/dc05-1365 · Cited by 627
Research works printed but not linked: 3
- Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook
- Chiang, 2014, Type 1 diabetes through the life span: a position statement of the American Diabetes Association
- Lipska, 2018, Association of initiation of basal insulin analogs vs neutral protamine hagedorn insulin with hypoglycemia-related emergency department visits or hospital admissions and with glycemic control in patients with type 2 diabetes, 53
Cited by
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690
Joseph, J. J., Deedwania, P., Acharya, T., Aguilar, D., Bhatt, D. L., Chyun, D. A., Di Palo, K. E., Golden, S. H., Sperling, L. S., & on behalf of the American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Arteriosclerosis, T. A. V. B. C. O. C. C. A. C. O. H. (2022) · Circulation · doi:10.1161/cir.0000000000001040 · Cited by 660
Kanwal, F., Shubrook, J. H., Adams, L. A., Pfotenhauer, K., Wai-Sun Wong, V., Wright, E., Abdelmalek, M. F., Harrison, S. A., Loomba, R., Mantzoros, C. S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.07.049 · Cited by 618
“78”
Nordanstig, J., Behrendt, C.-A., Baumgartner, I., Belch, J., Bäck, M., Fitridge, R., Hinchliffe, R., Lejay, A., Mills, J. L., Rother, U., et al. (2024) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2023.08.067 · Cited by 515
Gastaldelli, A., Cusi, K., Fernández Landó, L., Bray, R., Brouwers, B., & Rodríguez, Á. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00070-5 · Cited by 513
Korytkowski, M. T., Muniyappa, R., Antinori-Lent, K., Donihi, A. C., Drincic, A. T., Hirsch, I. B., Luger, A., McDonnell, M. E., Murad, M. H., Nielsen, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac278 · Cited by 315
Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., & Targher, G. (2021) · Metabolites · doi:10.3390/metabo11020073 · Cited by 299
“In fact, GLP-1 RAs are efficacious for treatment of T2DM and are also able to promote significant weight loss (on average 4–5 kg) [51].”
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression
Naaman, S. C., & Bakris, G. L. (2023) · Diabetes Care · doi:10.2337/dci23-0030 · Cited by 292
GLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
Sodium-Glucose Cotransporter 2 Inhibitors Mechanisms of Action: A Review
Fonseca-Correa, J. I., & Correa-Rotter, R. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.777861 · Cited by 277
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
Association of metabolic dysfunction-associated fatty liver disease with kidney disease
Wang, T.-Y., Wang, R.-F., Bu, Z.-Y., Targher, G., Byrne, C. D., Sun, D.-Q., & Zheng, M.-H. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00519-y · Cited by 210
Glycemia Reduction in Type 2 Diabetes — Glycemic Outcomes
The GRADE Study Research Group (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2200433 · Cited by 222
Pullano, S. A., Greco, M., Bianco, M. G., Foti, D., Brunetti, A., & Fiorillo, A. S. (2022) · Theranostics · doi:10.7150/thno.64035 · Cited by 210
Safety of GLP-1 Receptor Agonists and Other Second-Line Antidiabetics in Early Pregnancy
Cesta, C. E., Rotem, R., Bateman, B. T., Chodick, G., Cohen, J. M., Furu, K., Gissler, M., Huybrechts, K. F., Kjerpeseth, L. J., Leinonen, M. K., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.6663 · Cited by 200
Kidney disease in diabetes: From mechanisms to clinical presentation and treatment strategies
Ricciardi, C. A., & Gnudi, L. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154890 · Cited by 190
Tsapas, A., Karagiannis, T., Kakotrichi, P., Avgerinos, I., Mantsiou, C., Tousinas, G., Manolopoulos, A., Liakos, A., Malandris, K., Matthews, D. R., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14451 · Cited by 179
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Patel Chavez, C., Cusi, K., & Kadiyala, S. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab578 · Cited by 162
Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
Nakhleh, A., & Shehadeh, N. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i12.2036 · Cited by 154
Stempniewicz, N., Vassalotti, J. A., Cuddeback, J. K., Ciemins, E., Storfer-Isser, A., Sang, Y., Matsushita, K., Ballew, S. H., Chang, A. R., Levey, A. S., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2715 · Cited by 157
Shin, J.-I., Chang, A. R., Grams, M. E., Coresh, J., Ballew, S. H., Surapaneni, A., Matsushita, K., Bilo, H. J. G., Carrero, J. J., Chodick, G., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17323 · Cited by 155
Diabetic foot ulcer: Challenges and future
Li, Y., Rong, G.-C., & Wu, Q. (2022) · World Journal of Diabetes · doi:10.4239/wjd.v13.i12.1014 · Cited by 188
Weiss, T., Yang, L., Carr, R. D., Pal, S., Sawhney, B., Boggs, R., Rajpathak, S., & Iglay, K. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002517 · Cited by 152
Simms-Williams, N., Treves, N., Yin, H., Lu, S., Yu, O., Pradhan, R., Renoux, C., Suissa, S., & Azoulay, L. (2024) · BMJ · doi:10.1136/bmj-2023-078242 · Cited by 151
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140
Karagiannis, T., Tsapas, A., Athanasiadou, E., Avgerinos, I., Liakos, A., Matthews, D. R., & Bekiari, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108737 · Cited by 146
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., & Reimondo, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738848 · Cited by 143
Mahtta, D., Ramsey, D. J., Lee, M. T., Chen, L., Al Rifai, M., Akeroyd, J. M., Vaughan, E. M., Matheny, M. E., Santo, K. R. D. E., Navaneethan, S. D., et al. (2022) · Diabetes Care · doi:10.2337/dc21-1815 · Cited by 137
Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.057934 · Cited by 132
The benefits of GLP1 receptors in cardiovascular diseases
Ferhatbegović, L., Mršić, D., & Macić-Džanković, A. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1293926 · Cited by 127
“Maintaining stable blood glucose levels through lifestyle modi fi cations and medications can mitigate the adverse effects of hyperglycemia on blood vessels, thereby contributing to CVD risk reduction in diabetic patients (48, 49).”
BackgroundLi, S., Vandvik, P. O., Lytvyn, L., Guyatt, G. H., Palmer, S. C., Rodriguez-Gutierrez, R., Foroutan, F., Agoritsas, T., Siemieniuk, R. A. C., Walsh, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1091 · Cited by 123
The interplay between diabetes mellitus and menopause: clinical implications
Lambrinoudaki, I. V., Paschou, S. Α., Armeni, E., & Goulis, D. G. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00708-0 · Cited by 154
Personalized type 2 diabetes management: an update on recent advances and recommendations
Williams, D. M., Jones, H., & Stephens, J. W. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s331654 · Cited by 121
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
Yang, Z., Lv, Y., Yu, M., Mei, M., Xiang, L., Zhao, S., & Li, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.925377 · Cited by 120
Type 1 diabetes glycemic management: Insulin therapy, glucose monitoring, and automation
Perkins, B. A., Sherr, J. L., & Mathieu, C. (2021) · Science · doi:10.1126/science.abg4502 · Cited by 122
Pradhan, R., Lu, S., Yin, H., Yu, O. H. Y., Ernst, P., Suissa, S., & Azoulay, L. (2022) · BMJ · doi:10.1136/bmj-2022-071380 · Cited by 111
Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction
Udell, J. A., Jones, W. S., Petrie, M. C., Harrington, J., Anker, S. D., Bhatt, D. L., Hernandez, A. F., & Butler, J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.353 · Cited by 117
Massimino, E., Izzo, A., Riccardi, G., & Della Pepa, G. (2021) · Cells · doi:10.3390/cells10081958 · Cited by 102
Patorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103
Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression
Wang, N., & Zhang, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063086 · Cited by 139
“GLP-1RAs were recommended for DKD patients to gain better glycemic treatment even after optimizing treatment with SGLT2 inhibitors [31].”
BackgroundPersonalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
Williams, D. M., Jones, H. F., & Stephens, J. W. (2022) · Dove Medical Press (Taylor and Francis Group) · Cited by 99
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Martino, A. D., Albanese, G., Marfella, R., Sardu, C., et al. (2021) · Biomolecules · doi:10.3390/biom11121834 · Cited by 102
Elhussein, A., Anderson, A., Bancks, M. P., Coday, M., Knowler, W. C., Peters, A., Vaughan, E. M., Maruthur, N. M., Clark, J. M., & Pilla, S. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100111 · Cited by 92
Piragine, E., Petri, D., Martelli, A., Calderone, V., & Lucenteforte, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051981 · Cited by 149
Obesity in Patients with Type 1 Diabetes: Links, Risks and Management Challenges
Vilarrasa, N., San Jose, P., Rubio, M. Á., & Lecube, A. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s223618 · Cited by 88
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 103
Choi, J. G., Winn, A. N., Skandari, M. R., Franco, M. I., Staab, E. M., Alexander, J., Wan, W., Zhu, M., Huang, E. S., Philipson, L., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-2941 · Cited by 87
Sex Differences in Cardiovascular Consequences of Hypertension, Obesity, and Diabetes
Regensteiner, J. G., & Reusch, J. E. B. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.010 · Cited by 87
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
Polonsky, W. H., ARORA, R., Faurby, M. D., Fernandes, J. D. D. R., & Liebl, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01189-6 · Cited by 99
Chen, J.-J., Wu, C.-Y., Jenq, C.-C., Lee, T.-H., Tsai, C.-Y., Tu, H.-T., Huang, Y.-T., Yen, C.-L., Yen, T.-H., Chen, Y.-C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1169 · Cited by 82
Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population
Zaghlool, S. B., Halama, A., Stephan, N., Gudmundsdottir, V., Gudnason, V., Jennings, L. L., Thangam, M., Ahlqvist, E., Malik, R. A., Albagha, O. M. E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34754-z · Cited by 79
Prattichizzo, F., de Candia, P., & Ceriello, A. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154799 · Cited by 82
Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin
Vaduganathan, M., Sattar, N. A., Xu, J., Butler, J., Mahaffey, K. W., Neal, B. C., Shaw, W. C., Rosenthal, N. R., Pfeifer, M., Hansen, M. K., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.11.027 · Cited by 79
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
The Most Undertreated Chronic Disease: Addressing Obesity in Primary Care Settings
Tucker, S., Bramante, C., Conroy, M., Fitch, A., Gilden, A., Wittleder, S., & Jay, M. (2021) · Current Obesity Reports · doi:10.1007/s13679-021-00444-y · Cited by 73
Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
Reilhac, C., Dubourg, J., Thang, C., Grouin, J., Fouqueray, P., & Watada, H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14642 · Cited by 86
Maiorino, M. I., Longo, M., Scappaticcio, L., Bellastella, G., Chiodini, P., Esposito, K., & Giugliano, D. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01401-8 · Cited by 72
Friedreich Ataxia: Multidisciplinary Clinical Care
Lynch, D. R., Schadt, K. A., Kichula, E. A., McCormack, S. E., & Lin, K. Y. (2021) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s292945 · Cited by 75
Abdelaziz, M. A., Shaldam, M. A., El-Domany, R. A., & Belal, F. F. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.120298 · Cited by 72
Zhuo, M., Hawley, C. E., Paik, J. M., Bessette, L. G., Wexler, D. J., Kim, D. H., Tong, A. Y., Kim, S. C., & Patorno, E. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.30762 · Cited by 78
Carlson, A. L., Daniel, T. D., DeSantis, A., Jabbour, S., Karslioglu French, E., Kruger, D., Miller, E., Ozer, K., & Elliott, T. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002590 · Cited by 69
Giugliano, D., Longo, M., Caruso, P., Di Fraia, R., Scappaticcio, L., Gicchino, M., Petrizzo, M., Bellastella, G., Maiorino, M. I., & Esposito, K. (2021) · Diabetes Care · doi:10.2337/dc20-2623 · Cited by 69
The role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 79
Fitzgerald, I., O’Connell, J., Keating, D., Hynes, C., McWilliams, S., & Crowley, E. K. (2021) · Evidence-Based Mental Health · doi:10.1136/ebmental-2021-300291 · Cited by 84
Alhaddad, A. Y., Aly, H., Gad, H., Al-Ali, A. K., Sadasivuni, K. K., Cabibihan, J., & Malik, R. A. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.876672 · Cited by 77
“…(ADA) clinical practice recommendations to achieve optimal blood glucose targets using different therapies (American Diabetes Association, 2020a; American Diabetes Association, 2020b), but are inherently associated with an increased risk of hypoglycemia (Ohkuma et al., 2021), especially in…”
BackgroundSeisa, M. O., Saadi, S., Nayfeh, T., Muthusamy, K., Shah, S. H., Firwana, M., Hasan, B., Jawaid, T., Abd-Rabu, R., Korytkowski, M. T., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac277 · Cited by 65
Yoshida, Y., Joshi, P., Barri, S., Wang, J., Corder, A. L., O'Connell, S. S., & Fonseca, V. A. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108255 · Cited by 65
Treatment of chronic kidney disease in older populations
Kishi, S., Kadoya, H., & Kashihara, N. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00854-w · Cited by 73
“This gap in access is particularly pronounced in low-income regions 9,10 .”
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment
Cherney, D. Z. I., Ferrannini, E., Umpierrez, G. E., Peters, A. L., Rosenstock, J., Carroll, A. K., Lapuerta, P., Banks, P. L., & Agarwal, R. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14513 · Cited by 73
An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes
Giglio, R. V., Παπάνας, Ν., Rizvi, A. A., Ciaccio, M., Patti, A. M., Ilias, Ι., Stoian, A. P., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Medicina · doi:10.3390/medicina58101475 · Cited by 81
Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0393 · Cited by 63
Rotkvić, P. G., Planinić, Z., Pršo, A.-M. L., Šikić, J., Galić, E., & Rotkvić, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115973 · Cited by 66
Basal weekly insulins: the way of the future!
Rosenstock, J., & Prato, S. D. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154924 · Cited by 76
Nigussie, S., Birhan, N., Amare, F., Mengistu, G., Adem, F., & Abegaz, T. M. (2021) · PLOS ONE · doi:10.1371/journal.pone.0251506 · Cited by 62
SGLT-2 inhibitors as cardio-renal protective agents
Caruso, I., & Giorgino, F. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154937 · Cited by 63
Emerging role of neutrophil extracellular traps in the complications of diabetes mellitus
Shafqat, A., Rab, S. A., Ammar, O., Alsalameh, S., Alkhudairi, A., Kashir, J., AlKattan, K. M., & Yaqinuddin, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.995993 · Cited by 67
Colombijn, J. M. T., Idema, D. L., van Beem, S., Blokland, A. M., van der Braak, K., Handoko, M. L., Veld, L. F. H. I. ’., Kaul, T., Kolagasigil-Akdemir, N., Kusters, M. P. T., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.0427 · Cited by 75
Metformin targets mitochondrial complex I to lower blood glucose levels
Reczek, C. R., Chakrabarty, R. P., D’Alessandro, K. B., Sebo, Z. L., Grant, R. A., Gao, P., Budinger, G. R. S., & Chandel, N. S. (2024) · Science Advances · doi:10.1126/sciadv.ads5466 · Cited by 72
Franco, N. H., Miranda, S. B., Kovács, N., Nagy, A. C., Thiện, B. Q., Reis, F., & Varga, O. (2021) · Biology · doi:10.3390/biology10020155 · Cited by 60
Tanabe, H., Masuzaki, H., & Shimabukuro, M. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109067 · Cited by 62
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 58
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 70
Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study
Gharib, M., El-Baz, W., Darweesh, E. A. G., Sabri, N. A., & Shawki, M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.726490 · Cited by 60
Kazda, C. M., Bue-Valleskey, J. M., Chien, J., Zhang, Q., Chigutsa, E., Landschulz, W., Wullenweber, P., Haupt, A., & Dahl, D. (2023) · Diabetes Care · doi:10.2337/dc22-2395 · Cited by 56
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Lau, K. T. K., Ng, L., Wong, J. W. H., Loong, H. H.-F., Chan, W., Lee, C., & Wong, C. K. H. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09675-9 · Cited by 56
Mascolo, A., Scavone, C., Scisciola, L., Chiodini, P., Capuano, A., & Paolisso, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105836 · Cited by 60
Granata, A., Maccarrone, R., Anzaldi, M., Leonardi, G., Pesce, F., Amico, F., Gesualdo, L., & Corrao, S. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac069 · Cited by 54
Patorno, E., Pawar, A. M., Wexler, D. J., Glynn, R. J., Bessette, L. G., Paik, J. M., Najafzadeh, M., Brodovicz, K. G., Déruaz‐Luyet, A., & Schneeweiß, S. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14593 · Cited by 62
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
Han, T., Ma, S., Sun, C., Zhang, H., Qu, G., Chen, Y., Cheng, C., Chen, E. L., Ahmed, M. A., Kim, K. Y., et al. (2021) · Archives of Medical Research · doi:10.1016/j.arcmed.2021.08.002 · Cited by 59
Recommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 63
Xu, J., Hirai, T., Koya, D., & Kitada, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm11010137 · Cited by 57
Impairment of Mitochondrial Respiration in Metabolic Diseases: An Overview
Avram, V. F., Merce, A. P., Hâncu, I. M., Bătrîn, A. D., Kennedy, G., Rosca, M. G., & Muntean, D. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168852 · Cited by 54
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 62
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
Metadata
- Authors
- American Diabetes Association
- Corresponding author
- American Diabetes Association
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-12-04
- Volume
- 44
- Issue
- Supplement_1
- Pages
- S111-S124
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4254445254
- Cited by
- 972
- References
- 94
- Citations by year
- 2026: 29 · 2025: 55 · 2024: 86 · 2023: 148 · 2022: 334 · 2021: 318 · 2020: 1
- FWCI
- 30.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- pharmacotherapy, diabetes management, antidiabetic drugs, treatment goals, quality of care, clinical guidelines
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Endocrinology, Humans, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.